ASCEND BY NTHRYS
Research Abroad Products

Genetics Project Topics

Browse all focused areas across all project categories under this field.

Showing 1405–1416 of 2020 project topics
TP53 Li-Fraumeni Syndrome Comprehensive Screening Platform
A cloud-based diagnostic platform that integrates TP53 mutation detection with multi-cancer risk stratification algorithms for connective tissue and soft tissue sarcomas. This SaaS solution enables oncology centers to offer tiered surveillance protocols and personalized treatment recommendations, generating recurring licensing revenue and premium data analytics services.
Genetic Basis of Connective Tissue Tumors Click to view more details →
DICER1 Pleuropulmonary Blastoma Genetic Risk Assessment Tool
An automated genetic testing and interpretation service that identifies DICER1 pathogenic variants associated with pleuropulmonary blastoma and other connective tissue malignancies. The platform delivers commercial value through pre-natal counseling integrations, pediatric surveillance recommendations, and subscription-based family monitoring dashboards for healthcare systems.
Genetic Basis of Connective Tissue Tumors Click to view more details →
PTEN Cowden Syndrome Connective Tissue Malignancy Intelligence
A predictive analytics software suite that maps PTEN mutations to connective tissue tumor phenotypes and generates precision surveillance calendars for Cowden syndrome patients. This tool monetizes through enterprise healthcare system contracts, insurance pre-authorization optimization, and advanced tumor progression forecasting modules.
Genetic Basis of Connective Tissue Tumors Click to view more details →
MDM2 Amplification Soft Tissue Sarcoma Stratification Engine
A next-generation sequencing interpretation platform that quantifies MDM2 amplification levels to predict therapy response and progression risk in well-differentiated liposarcomas and leiomyosarcomas. Revenue streams include NGS panel licensing, companion diagnostic certification, and integration partnerships with pharmaceutical companies developing MDM2 inhibitor therapies.
Genetic Basis of Connective Tissue Tumors Click to view more details →
BAP1 Mesothelioma and Uveal Melanoma Genetic Testing Registry
A specialized genetic testing and longitudinal tracking service that detects BAP1 germline mutations in patients with pleural mesothelioma, connective tissue malignancies, and related cancers. This platform generates revenue through test volume scaling, family cascade screening programs, and occupational exposure risk databases sold to industrial hygiene consultants.
Genetic Basis of Connective Tissue Tumors Click to view more details →
BRCA1/2 Connective Tissue Sarcoma Integrated Reporting System
A comprehensive clinical reporting platform that combines BRCA1/2 testing results with sarcoma-specific genetic signatures to guide treatment decisions and surveillance protocols. The system monetizes through laboratory information system integrations, institutional licensing agreements, and value-added oncologist consultation services for treatment optimization.
Genetic Basis of Connective Tissue Tumors Click to view more details →
Enlarged Vestibular Aqueduct SLC26A4 Testing
Characterizing SLC26A4 variants causing enlarged vestibular aqueduct and Pendred syndrome for molecular diagnosis and thyroid evaluation guidance.
Genetic Basis of Hearing and Vestibular Disorders Click to view more details →
DFNA and DFNB Locus Molecular Characterization
Characterizing genes at autosomal dominant and recessive deafness loci using positional cloning and candidate gene approaches in deaf families.
Genetic Basis of Hearing and Vestibular Disorders Click to view more details →
Auditory Neuropathy Spectrum Disorder Genetics
Testing OTOF, DIAPH3, and other genes causing auditory neuropathy spectrum disorder for molecular diagnosis and cochlear implant candidacy assessment.
Genetic Basis of Hearing and Vestibular Disorders Click to view more details →
Familial Meniere Disease Genetic Analysis
Investigating genetic contributors to familial Meniere disease including COCH and MYO7A variants for understanding vestibular disorder genetics.
Genetic Basis of Hearing and Vestibular Disorders Click to view more details →
GJB2 GJB6 Mutation Detection SaaS Platform
A cloud-based diagnostic platform that rapidly identifies connexin gene mutations responsible for nonsyndromic hearing loss through high-throughput sequencing and automated variant interpretation. This service generates recurring revenue through per-test subscriptions and laboratory partnerships while reducing time-to-diagnosis from weeks to days.
Genetic Basis of Hearing and Vestibular Disorders Click to view more details →
Mitochondrial Hearing Loss m.1555A>G Screening Tool
A specialized genetic screening instrument designed to detect maternally inherited mitochondrial mutations associated with aminoglycoside-induced deafness in clinical and pharmaceutical settings. This tool creates B2B revenue through hospital licensing agreements and enables pharmaceutical companies to identify at-risk populations for drug safety monitoring.
Genetic Basis of Hearing and Vestibular Disorders Click to view more details →